Search

Aims: One of the comorbidities associated with severe outcome and mortality of COVID-19 is dyslipidemia. Statin is one of the drugs which is most commonly used for the treatment of dyslipidemic patients. This study aims to analyze the association between statin use and composite poor outcomes of COVID-19.Data Synthesis: We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until November 25th, 2020. All articles published on COVID-19 and statin were retrieved. Statistical analysis was done using Review Manager 5.4 and Comprehensive Meta-Analysis 3 software.Results: A total of 35 studies with a total of 11, 930, 583 patients were included in our analysis. Our meta-analysis showed that statin use did not improve the composite poor outcomes of COVID-19 [OR 1.08 (95% CI 0.86-1.35), p = 0.50, I2 = 98%, random-effect modelling]. Meta-regression showed that the association with composite poor outcomes of COVID-19 was influenced by age (p = 0.010), gender (p = 0.045), and cardiovascular disease (p = 0.012). Subgroup analysis showed that the association was weaker in studies with median age ≥60 years-old (OR 0.94) compared to <60 years-old (OR 1.43), and in the prevalence of cardiovascular disease ≥25% (RR 0.94) compared to <25% (RR 1.24).Conclusion: Statin use did not improve the composite poor outcomes of COVID-19. Patients with dyslipidemia should continue taking statin drugs despite COVID-19 infection status, given its beneficial effects on cardiovascular outcomes. [ABSTRACT FROM AUTHOR]

Background: Laboratory testing is commonly performed in patients with COVID-19. Each of the laboratory parameters has potential value for risk stratification and prediction of COVID-19 outcomes. This systematic review and meta-analysis aimed to evaluate the difference between these parameters in severe and nonsevere disease and to provide the optimal cutoff value for predicting severe disease.Method: We performed a systematic literature search through electronic databases. The variables of interest were serum procalcitonin, albumin, C-reactive protein (CRP), D-dimer, and lactate dehydrogenase (LDH) levels in each group of severity outcomes from COVID-19.Results: There were a total of 4848 patients from 23 studies. Our meta-analysis suggest that patients with severe COVID-19 infections have higher procalcitonin, (mean difference 0.07; 95% CI 0.05-0.10; p < 0.00001), CRP (mean difference 36.88; 95% CI 29.10-44.65; p < 0.00001), D-Dimer (mean difference 0.43; 95% CI 0.31-0.56; p < 0.00001), and LDH (mean difference 102.79; 95% CI 79.10-126.49; p < 0.00001) but lower levels of albumin (mean difference -4.58; 95% CI -5.76 to -3.39; p < 0.00001) than those with nonsevere COVID-19 infections. The cutoff values for the parameters were 0.065 ng/mL for procalcitonin, 38.85 g/L for albumin, 33.55 mg/L for CRP, 0.635 μ/L for D-dimer, and 263.5 U/L for LDH, each with high sensitivity and specificity.Conclusion: This meta-analysis suggests elevated procalcitonin, CRP, D-dimer, and LDH and decreased albumin can be used for predicting severe outcomes in COVID-19. [ABSTRACT FROM AUTHOR]

• The role of COVID-19 survivor towards antibody titers post-Sinovac vaccination are unknown • The gender role towards antibody titers post-Sinovac vaccination are also unknown • COVID-19 survivorship was associated with higher antibody titers during first two months • Females had higher antibody titers than males in all 3 months after vaccination Male and female titers differed most in the 1 month and 3 months after vaccination Background: Sinovac was the first vaccine used in Indonesia against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, data regarding the effects of certain variables such as clinical demographics on antibody levels in individuals vaccinated with Sinovac are scarce. This study aimed to investigate the impact of gender and previous SARS-CoV-2 infection status on neutralizing antibody titers 1, 2, and 3 months after administration of the Sinovac vaccine. Method: A cross-sectional study was conducted from February to May 2021. Data on neutralizing antibody levels, previous SARS-CoV-2 infection status, and gender were retrieved from the monthly quantitative serology evaluation database of Siloam Hospitals Lippo Village, Tangerang, Indonesia. The role of each variable was analyzed using the t -test or Mann-Whitney U test, depending on data distribution. Result: Data from 350 participants were collected for the study. Participants with a history of a positive SARS-CoV-2 RT-PCR test had significantly higher neutralizing antibody titers in the first (144 U/mL, p = 0.036) and second months (144 U/mL, p = 0.005) after vaccination compared with those without a history of positive RT-PCR test. Female participants also had significantly higher neutralizing antibody titers in the first, second, and third months (43 U/mL, 42 U/mL, and 39 U/mL, respectively; p = 0.001, p = 0.002, and p = 0.003, respectively) after vaccination compared to males. Conclusion: COVID-19 survivor status and the female gender were associated with higher neutralizing antibody titers after Sinovac vaccine administration. [ABSTRACT FROM AUTHOR]

The coronavirus disease 2019 (COVID-19) number of death cases is still increasing. One of the comorbidities associated with severe outcome and mortality of COVID-19 is dyslipidemia. Statin is one of the drugs which is most commonly used for the treatment of dyslipidemic patients. This study aims to analyze the association between statin use and in-hospital outcomes of COVID-19 infection. We systematically searched the Google Scholar database using specific keywords related to our aims until August 1st, 2020. All articles published on COVID-19 and statin were retrieved. Statistical analysis was done using Review Manager 5.4 software. A total of 9 studies with a total of 3449 patients were included in our analysis. Our meta-analysis showed that statin use did not improve severity outcome [OR 1.64 (95% CI 0.51–5.23), p = 0.41, I 2 = 93%, random-effect modelling] nor mortality rate from COVID-19 infection [OR 0.78 (95% CI 0.50–1.21), p = 0.26, I 2 = 0%, fixed-effect modelling]. Statin use did not improve in-hospital outcomes of COVID-19 infections. Patients with dyslipidemia should continue taking statin drugs despite COVID-19 infection status, given its beneficial effects on cardiovascular outcomes. • Currently, evidence regarding benefit of statin in COVID-19 is not supported by sufficient human studies. • Our meta-analysis showed that statin use did not improve in-hospital outcomes of patients with COVID-19 infections. • Patients with dyslipidemia should continue taking statin if they develop COVID-19. [ABSTRACT FROM AUTHOR]

The number of positive and death cases from coronavirus disease 2019 (COVID-19) is still increasing. The identification of risk factors for severe outcomes is important. Dyslipidemia has been shown as a long-known risk factor for cardiovascular disease. The aim of this study is to analyze the potential association between dyslipidemia and the severity of COVID-19 infection. We systematically searched the PubMed database using specific keywords related to our aims until July 9th, 2020. All articles published on COVID-19 and dyslipidemia were retrieved. Statistical analysis was done using Review Manager 5.4 software. A total of 7 studies with a total of 6922 patients were included in our analysis. Our meta-analysis showed that dyslipidemia is associated with severe COVID-19 infections [RR 1.39 (95% CI 1.03–1.87), p = 0.03, I 2 = 57%, random-effect modelling]. Dyslipidemia increases the risk of the development of severe outcomes from COVID-19 infections. Patients with dyslipidemia should be monitored closely to minimize the risk of COVID-19. • Our meta-analysis showed that dyslipidemia is associated with severe COVID-19 infections. • Patients with dyslipidemia should be monitored closely to minimize the risk of COVID-19. • The presence of dyslipidemia should be considered for further risk stratification of COVID-19. [ABSTRACT FROM AUTHOR]

Background Low muscle mass is one of the prognostic factor that may lead to negative outcome and is the major feature of cancer cachexia, including breast cancer. Sarcopenia is associated with reduced quality of life (QoL) and survival. There is limited data reported about this association. The aim of this study is to know the comparison between low muscle mass and Quality of Life in Indonesian Breast Cancer Patients. Methods The data was collected using cross-sectional Method from October 2018- February 2019. Patients who had breast cancer and have underwent chemotherapy are included in this study and evaluated using BR-23 questionnaire, and Bioelectric Impedance Analysis (BIA) to assess their muscle mass with the cut-off of 5.7 kg/m2. the comparison between both lower muscle mass and higher muscle mass to QoL are evaluated using t-test in SPSS version 24.0. Result From 36 patients with mean age 48.28 +- 9.8 , median muscle mass is 5.92 ranged from 4.48 to 8.32. Patient with low muscle mass had functional mean of QoL 54.55% +-8.45 and symptoms mean of QoL 85.34% +- 3.09. while Patient with normal muscle mass had functional mean of QoL 56.02% +-8.8 and symptoms mean of QoL 86.51+-12.05. The Association between muscle mass and QoL is defined as p-value of 0.658. Conclusion Patients with low muscle mass have lower QoL, whereas patient with high muscle mass have better QoL. However, muscle mass association to quality of life is still unclear. Thus, further study with greater sample is needed to confirm the result [ABSTRACT FROM AUTHOR]

Background As of 2012¸ breast cancer accounts for 59% prevalence rate in Asia. The WHO identifies breast cancer as leading cancer in Indonesian women with 48.998 cases in 2014 with 48.9% incidence rate as well as 21.4% mortality rate out of 92.220 total deaths caused by cancers. Based on a research done in the UŞ initial diagnosis has evoked a state of shocķ fear and disbelief for the patients. Most women experience at least some psychosocial distress during the course of their breast cancer diagnosis. Even after appropriate treatments, 18% of women had posttraumatic stress symptomş many reported lymphedema (27%) and numbness (20%) as persistent problems. This contributed to significant psychosocial distress that can interfere with functioning which makes it necessary to assess the QoL within Indonesian femalés breast cancer patients. Objective The objective of this study was to test the reliability and validity of the Indonesian version of the EORTC QLQ-BR23 to assess the health-related quality of life of women with breast cancer in Indonesia. Methods The QLQ-BR23 questionnaire were distributed to 25 breast cancer patients in the Oncology Department of Siloam General Hospitaļ Karawaci¸ Tangerang. Data were collected using Microsoft Excel 2016 and was analyzed using SPSS 21.0 with descriptive statistic and pearson correlation statistics. Results Kolmogorov¯Smirnov test and Shapiro¯Wilk test for age showed results > 0.05 which indicates a normal distribution. Howeveŗ item statistics for Blr, SFr, Ser, FPr, STSEr, BSr, ASr and UHLr all showed a relatively low Cronbach's Alpha (<0.70) ranging from 0.378 to 0.56 which implies a low internal reliability. Conclusions In generaļ the findings of this study indicated that the Indonesian version of QLQ-BR23 validation that we did has not met the hypothesis and expected results. Further study is needed to achieve more reliable results. [ABSTRACT FROM AUTHOR]

Delirium is a common presenting symptom among older patients. Patients who presented with delirium may have a higher morbidity and mortality rate due to older age, other comorbidities, and atypical COVID-19 presentation. Currently, the evidence supporting delirium as one of the predictors of poor outcome of COVID-19 is still insufficient. This study aims to explore the potential association between delirium and poor outcomes from COVID-19. We systematically searched the PubMed and Google Scholar databases using specific keywords related to our aims until January 30th, 2021. All articles published on COVID-19 and delirium were retrieved. The quality of the study was assessed using the Newcastle Ottawa Scale (NOS) tool for observational studies and Joanna Briggs Institute (JBI) Critical Appraisal Tools for case-series studies. Statistical analysis was done using Review Manager 5.4 software. Our meta-analysis of 20 studies showed that delirium symptoms on admission was associated with poor outcomes from COVID-19 [OR 2.36 (95% CI 1.80–3.09), p < 0.00001, I 2 = 76%, random-effect models] and its subgroup which consist of severe COVID-19 [OR 3.89 (95% CI 1.72–8.75), p = 0.001, I 2 = 91%, random-effect models], and mortality from COVID-19 [OR 1.90 (95% CI 1.55–2.33), p < 0.00001, I 2 = 36%, random-effect models]. Meta-regression showed that the association was influenced by age (p = 0.005). Our study suggests delirium as an important marker to identify patients at higher risk for developing poor COVID-19 outcomes. The physicians should add delirium as one of the common presenting symptoms of COVID-19 in older populations. • Currently, evidence supporting delirium as the predictors for poor COVID-19 is still lacking. • Our meta-analysis showed that delirium are associated with poor outcomes from COVID-19. • The relationship between delirium and poor COVID-19 outcomes is influenced by age. • Physicians should consider delirium as important markers of poor COVID-19 in older populations. [ABSTRACT FROM AUTHOR]

Background: Parkinson's Disease (PD) is among one of the common comorbidities in older patients. People with PD may be more vulnerable to severe pneumonia, due to the impairment of pulmonary function. Currently, the association between PD and COVID-19 is not yet established. This study aims to analyze the relationship between PD and in-hospital outcomes of COVID-19.Materials and Methods: We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until December 25th, 2020. All articles published on COVID-19 and Parkinson's Disease were retrieved. The quality of the study was assessed using the Newcastle Ottawa Scale (NOS) tool for observational studies and Joanna Briggs Institute (JBI) Critical Appraisal Tools for cross-sectional studies. Statistical analysis was done using Review Manager 5.4 software.Results: A total of 12 studies with 103,874 COVID-19 patients were included in this meta-analysis. This meta-analysis showed that Parkinson's Disease was associated with poor in-hospital outcomes [[OR 2.64 (95% CI 1.75-3.99), p < 0.00001, I2 = 81%] and its subgroup which comprised of severe COVID-19 [OR 2.61 (95% CI 1.98-3.43), p < 0.00001, I2 = 0%] and mortality from COVID-19 [RR 2.63 (95% CI 1.50-4.60), p = 0.0007, I2 = 91%]. Meta-regression showed that the association was influenced by age (p = 0.05), but not by gender (p = 0.46) and dementia (p = 0.23).Conclusions: Extra care and close monitoring should be provided to Parkinson's Disease patients to minimize the risk of infections, preventing the development of severe and mortality outcomes. [ABSTRACT FROM AUTHOR]

Background Chemotherapy, as treatment, may responsible for undesired side effects, such as sarcopenia and chemotherapy toxicity. Based on the previous study, slow muscle mass may increase hematological toxicity and decrease response of chemotherapy effectiveness. The reported data about hematological chemotherapy toxicity and low muscle mass in Indonesian breast cancer patients is very limited thus the aim of this study to find out the prevalence and association between them. Methods This was cross-sectional study, conducted in our general hospital at Tangerang, Indonesia. Muscle mass was measured using Bio Impedance analysis. The first step, Asian Working Group for Sarcopenia (AWGS) criteria is used to count muscle mass cut-off in Indonesian population by height-based muscle mass. AWGS recommends to define low muscle mass as below the mean minus 2 standard deviation. The second step, blood sample from breast cancer patients undergoing chemotherapy were taken consecutively. The cut-off for defining anemia is hemoglobin <12g/dL; leukopenia is leukocyte count <5.000/mm3, and thrombocytopenia is < 150.000/mm3. The Chi Square analysis was used to see the association. Results The first step of the study included 137 young adult women. Cut off point of muscle mass in Indonesian female was 4.781 kg/m2. The second step, a total of 36 breast cancer patients with mean age 48.08±9.73 were included. Anemia was found in 20 (54%) subjects, leukopenia in 2 (5.5%) subjects, thrombocytopenia in 1 (2.7%) subject. In this study, patient with low muscle mass only found in 1 of 37 patients. Conclusion Cut-off muscle mass for Indonesian female is 4.781kg/m2, lower than AWGS standard. There is no statistically significant between low muscle mass and hematological toxicity in breast cancer patient. Further study needs to be evaluated in bigger population to confirm this result. [ABSTRACT FROM AUTHOR]